Dr. Tony Holohan:

The licensing or authorisation of those vaccines will happen at a European level on behalf of all of the member states of the European Union, through the European Medicines Agency, EMA. As a country we are part of the joint procurement arrangements that will kick in for the provision of that vaccine to all of the member states of the EU that are part of that joint procurement process. If a vaccine becomes available earlier than the time period indicated, that is, the end of 2021, we would have access to that through the joint recurrent arrangements now in place.